Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

ImmunityBio, Inc. (IBRX) had Revenue of $51.24M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$51.24M
Net Income	$-230.38M
Cost of Goods Sold	$0.30M
Gross Profit	$50.94M
Operating Expenses	$112.94M
Operating Income	$-61.70M
Non-Operating Income/Expense	$-168.69M
Pre-Tax Income	$-230.39M
Normalized Pre-Tax Income	$-230.39M
Income after Taxes	$-230.39M
Income from Continuous Operations	$-230.39M
Consolidated Net Income/Loss	$-230.39M
Normalized Income after Taxes	$-230.39M
EBIT	$-61.70M
EBITDA	$-55.76M
Weighted-Average Shares Outstanding (Basic)	1.05B
Weighted-Average Shares Outstanding (Diluted)	1.05B
Earnings per Share (EPS) (Basic)	$-0.22
Earnings per Share (EPS) (Diluted)	$-0.22
Balance Sheet Financials
Current Assets	$438.98M
Property, Plant, and Equipment	$114.22M
Long-Term Assets	$189.52M
Total Assets	$628.50M
Current Liabilities	$76.73M
Long-Term Debt	$774.35M
Long-Term Liabilities	$1.60B
Total Liabilities	$1.67B
Common Equity	$-1.05B
Tangible Shareholders Equity	$-1.06B
Shareholders Equity	$-1.05B
Common Shares Outstanding	1.05B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-141.85M
Cash Flow from Investing Activities	$-139.12M
Cash Flow from Financial Activities	$268.37M
Beginning Cash	$89.43M
End Cash	$76.95M
Increase/Decrease in Cash	$-12.48M
Stock-Based Compensation	$16.69M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.72
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-2.85
Debt to Equity Ratio	-0.74
Gross Margin	99.42%
Operating Margin	-120.41%
EBIT Margin	-120.41%
EBITDA Margin	--
Pre-Tax Profit Margin	-449.63%
Profit Margin	-449.61%
Free Cash Flow	$-147.15M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.15
Receiveable Turnover	0.96
Days Sales in Receivables	93.92
Return on Equity	22.03%
Return on Tangible Equity	21.78%
Return on Assets	-36.66%
Return on Investments	84.89%
Book Value Per Share	$-0.99
Free Cash Flow per Share	$-0.14
Operating Cash Flow per Share	$-0.14

Data from Zacks Investment Research, Inc.